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ABSTRACT

ARTICLE HISTORY

On the basis of their training, medical students are considered “the best case scenario” among university
students in knowledge of the human papillomavirus (HPV). We evaluated differences in knowledge of
HPV, HPV vaccine, and head and neck cancer (HNC) among medical students. A previously validated
questionnaire was completed by 247 medical students at a Midwestern university. Outcomes of interest
were knowledge score for HPV and HPV vaccine, and HNC, derived from combining questionnaire items to
form HPV knowledge and HNC scores, and analyzed using multivariate linear regression. Mean scores for
HPV knowledge were 19.4 out of 26, and 7.2 out of 12 for HNC knowledge. In the final multivariate linear
regression model, sex, race, and year of study were independently associated with HPV and HPV vaccine
knowledge. Males had significantly lower HPV vaccine knowledge than females (β = −1.53; 95% CI: −2.53,
−0.52), as did nonwhite students (β = −1.05; 95% CI: −2.07, −0.03). There was a gradient in HPV vaccine
knowledge based on the year of study, highest among fourth year students (β = 6.75; 95% CI: 5.17, 8.33).
Results were similar for factors associated with HNC knowledge, except for sex. HNC knowledge similarly
increased based on year of study, highest for fourth year students (β = 2.50; 95% CI: 1.72, 3.29). Among
medical students, gaps remain in knowledge of HPV, HPV vaccine, and HPV-linked HNC. Male medical
students have significantly lower knowledge of HPV. This highlights the need to increase medical student
knowledge of HPV and HPV-linked HNC.
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Introduction
Human papillomavirus (HPV) is the most prevalent sexually
transmitted infection in the United States.1 In addition to
several anogenital and second primary malignancies,2–4 HPV
is linked to at least 72% of oropharyngeal cancer cases, a subset
of head and neck cancer (HNC).5 HPV-associated oropharyn
geal cancer has increased in incidence between 57% and 225%
in the last three decades and has now exceeded cervical cancer
as the most common HPV-associated cancer in the United
States.6–8 All approved vaccines are effective against HPV 16
and 18 which together are responsible for about 95% of HPVassociated oropharyngeal cancer.7 Five years after the initial
recommendation for adolescent girls, the HPV vaccine recom
mendation was expanded to include boys by the Advisory
Committee on Immunization Practices in 2011 with the goal
of preventing HPV-associated cancer. Furthermore, indica
tions for the HPV vaccine were recently expanded to include
prevention of HPV-associated oropharyngeal cancer.6,9
Although the HPV vaccine is safe and effective,10,11 it has
had limited uptake in the United States, especially in the
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eligible young adult population.12–15 There is strong evidence
that poor provider knowledge of HPV and inadequate physi
cian vaccine recommendations are contributors.16–20 Clinician
knowledge, communication ability, and comfort in providing
strong recommendations are critical to effective recommenda
tion of the vaccine.16,17,19,20
The medical student population is a unique population in
the context of HPV. They comprise the next generation of
pediatricians, family medicine physicians, and other primary
care clinicians who will lead conversations about the HPV
vaccine. However, they are also personally connected to the
HPV vaccine discourse as they are eligible for the vaccine
themselves. In fact, they often fall within the highest-risk age
group for HPV infection, an age group in which individuals are
more likely to experiment with oral sex, a primary risk factor
for oral HPV.21–24 Therefore, it is important to characterize
medical students’ understanding of HPV and its sequelae.
However, there remains a paucity of research investigating or
characterizing the gaps in HPV knowledge in this population,
particularly regarding HNC.
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Department of Head and Neck Surgery & Communication Sciences, Duke University School of
Medicine 40 Duke Medicine Circle, DukeSouth Yellow Zone 4080, DUMC 3805, Durham, NC 27710-4000, USA.
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

2

E. Y. DU ET AL.

Most of the HPV-related literature on medical and college
students in general has focused on knowledge and attitudes
about HPV and HPV vaccines without assessing knowledge of
HPV-associated HNC.25–28 Studies that focused on HNC had
limited study populations and sociodemographic analyses.29,30
Building on these previous studies, we aimed to (1) character
ize knowledge of HPV, HPV vaccine, and HPV-associated
HNC among medical students, and (2) determine demo
graphic and educational factors associated with differences in
knowledge.

Materials and methods
A cross-sectional study was conducted at a medical school in
the Midwest using a previously validated questionnaire
designed to elicit sociodemographic information and data
regarding HPV, the HPV vaccine, and HNC. This was admi
nistered via Qualtrics, a secure, web-based application
designed for data capture in research studies.31,32 The survey
was distributed online to all medical students 26 years or
younger. The age range was selected based on eligibility for
HPV vaccination at the time of survey, when recommenda
tions for the HPV vaccine were limited to the age of 26 years.
Also, previous studies have evaluated HPV vaccination with
this age cutoff.20,33 Participants were informed of the study
objectives, and informed consent was obtained. Responses to
the questionnaire were recorded anonymously. Participation
was non-mandatory, but monetary compensation (20.00 USD)
was offered to those who completed the survey and elected to
receive compensation. The questionnaire was administered to
311 medical students. Of these, 247 completed the survey,
yielding a response rate of 79%. This study was approved by
the university’s institutional review board.
Measures
The outcome measures were (1) knowledge about HPV and the
HPV vaccine, and (2) knowledge about HPV-associated HNC.
Knowledge about HPV and the HPV vaccine was assessed with
26 questions. Survey answers were scored as 1 for correct
responses and 0 for incorrect responses. Scores were then
summed to derive an HPV and HPV vaccine knowledge
score, for which the maximum score was 26 and the minimum
was 0. HPV-associated HNC knowledge was measured using
12 questions. These responses were scored as 1 for correct
responses and as 0 for incorrect responses. Scores were
summed to create an HPV-associated HNC knowledge score,
which ranged from 0 to 12. For both outcome measures,
a higher score represented higher knowledge. In addition,
specific knowledge questions regarding HPV’s association
with HNC and HPV’s association with cervical cancer (dichot
omized as yes/no) were analyzed.
The independent variables included year of study
(first, second, third, or fourth year), age, sex (male, female),
race (white, nonwhite [combining low-frequency responses]),
marital status (married, single but dating, single, and not dat
ing), and number of lifetime oral partners and number of
lifetime vaginal partners (zero, one, ≥ two), physician recom
mendation of HPV vaccine (yes, no), HPV vaccine initiation

(recipient of at least one dose), HPV vaccine completion (reci
pient of at least three doses), and specialty of interest (pedia
trics, family medicine, internal medicine, surgery, other
specialties).
Statistical analysis
Descriptive statistics were used to analyze the characteristics of
the respondents. Sociodemographic characteristics and sexual
behavioral risk factors were compared by year of study using
Pearson’s chi-square for categorical variables and one-way
ANOVA for continuous variables. Two multivariable linear
regression models were used to examine the association
between the two outcomes (HPV and HPV vaccine knowledge
and HPV-associated HNC knowledge) and sociodemographic
and sexual behavioral risk factors including year of study, sex,
race, marital status, number of oral sexual partners, and num
ber of vaginal sexual partners. Age was not included in the
adjusted model because it was highly correlated with year of
study. Adjusted β coefficients with corresponding 95% confi
dence intervals were reported for each variable. In addition,
two multivariable logistic regression models were used to
examine associations between knowledge of HPV’s association
with HNC or cervical cancer, and the same sociodemographic
and sexual behavioral risk factors listed above. Analyses were
performed using SAS statistical software version 9.4 (SAS
Institute Inc., Cary, NC). All statistical analyses were twotailed and used an alpha level of 0.05 to determine statistical
significance.

Results
Sample characteristics
A summary of the characteristics of the respondents in the study
sample is provided in Table 1. A total of 247 medical students
completed the questionnaire, of which 36.4% were first-years,
26.7% were second-years, 24.7% were third-years, and 12.2%
were fourth-years. The mean (SD) age of respondents was 24.0
(1.3), and the range was 23.0 (1.2) to 25.5 (0.6). More than half of
study respondents were female (56.1%, n = 139) and white
(60.1%, n = 149). Almost half 48.0% (n = 119) were married,
53% (n = 130) had multiple oral sexual partners, and 39% (n =
96) had multiple vaginal sexual partners. There was a statistically
significant difference in marital status (p = .0026), and provider
recommendation to receive HPV vaccine (p = .0336), based
on year of study. There was no statistical difference observed
in sex, race, number of oral sexual partners, number of vaginal
sexual partners, initiation of the HPV vaccine series, completion
of the HPV vaccine series, or specialty choice by year of study.
HPV and HPV vaccine knowledge
The mean (SD) HPV and HPV vaccine knowledge score was
19.4 (4.6) (Table 1). There was a gradient in HPV and HPV
vaccine knowledge score based on year of study: first-years
had score of 16.2 (4.6) and fourth-years had the highest score
of 23.3 (1.6) (Figure 1a). This was a statistically significant
difference (p < .001) (Figure 1a). There was no difference in
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Table 1. Sample characteristics.
Mean ± SD or n (%)
Year of study

HPV and the Vaccine Knowledge
HPV-associated HNC Knowledge
HPV causes HNC
Yes
No
HPV causes Cervical Cancer
Yes
No
Age
Sex
Female
Male
Race
White
Nonwhite
Marital status
Married
Single but Dating
Single and not Dating
Number of oral sexual partners
None
One
≥Two
Number of vaginal sexual partners
None
One
≥Two
Physician recommendation of HPV vaccine
Yes
No
HPV vaccine initiation
Yes
No
HPV vaccine completion
Yes
No
Specialty
Pediatrics
Family Medicine
Internal Medicine
Surgery
Other specialties

Total
n=247
19.4 ± 4.6
7.2 ± 2.1

First Year
90 (36.4)
16.2 ± 5.1
6.0 ± 1.9

Second Year
66 (26.7)
19.1 ± 3.6
7.4 ± 1.8

Third Year
61 (24.7)
22.2 ± 1.9
8.0 ± 1.8

Fourth Year
30 (12.2)
23.3 ± 1.6
8.7 ± 1.9

53 (21.5)
194 (78.5)

6 (6.7)
84 (93.3)

16 (24.2)
50 (75.8)

20 (32.8)
41 (67.2)

11 (36.7)
19 (63.3)

179 (72.5)
68 (27.5)
24.0 ± 1.3

48 (53.3)
42 (46.7)
23.0 ± 1.2

51 (77.3)
15 (22.7)
23.8 ± 1.1

56 (91.8)
5 (8.2)
24.8 ± 0.8

24 (80.0)
6 (20.0)
25.5 ± 0.6

139 (56.1)
109 (43.9)

54 (60.0)
36 (40.0)

41 (62.1)
25 (37.9)

26 (42.6)
35 (57.4)

17 (56.7)
13 (43.3)

149 (60.1)
99 (39.9)

52 (57.8)
38 (42.2)

36 (54.5)
30 (45.5)

37 (60.7)
24 (39.3)

23 (76.7)
7 (23.3)

119 (48.0)
50 (20.2)
79 (31.8)

39 (43.3)
18 (20.0)
33 (36.7)

37 (56.1)
11 (16.7)
18 (27.3)

33 (54.1)
6 (9.8)
22 (36.1)

10 (33.3)
14 (46.7)
6 (20.1)

57 (23.1)
60 (24.3)
130 (52.6)

25 (27.8)
18 (20.0)
47 (52.2)

13 (19.7)
18 (27.3)
35 (53.0)

15 (24.6)
16 (26.2)
30 (49.2)

4 (13.3)
8 (26.7)
18 (60.0)

82 (33.2)
69 (27.9)
96 (38.9)

36 (40.0)
19 (21.1)
35 (38.9)

20 (30.3)
22 (33.3)
24 (36.4)

19 (31.2)
18 (29.5)
24 (39.3)

7 (23.3)
10 (33.3)
13 (43.3)

129 (52.0)
119 (48.0)

54 (60.0)
36 (40.0)

36 (54.5)
30 (45.5)

22 (36.1)
39 (63.9)

16 (53.3)
14 (46.7)

124 (50.0)
124 (50.0)

46 (51.1)
44 (48.9)

35 (53.0)
31 (47.0)

25 (41.0)
36 (59.0)

17 (56.7)
13 (43.3)

102 (41.1)
146 (58.9)

40 (44.4)
50 (55.6)

29 (43.9)
37 (56.1)

19 (31.2)
42 (68.8)

14 (46.7)
16 (53.3)

48 (19.4)
26 (10.5)
64 (25.9)
41 (16.6)
68 (27.5)

19 (21.1)
8 (9.1)
23 (25.6)
17 (18.9)
23 (25.6)

10 (15.2)
6 (9.1)
15 (22.7)
8 (12.1)
27 (40.9)

11 (18.0)
9 (14.8)
16 (26.2)
10 (16.4)
15 (24.6)

8 (26.7)
3 (10.0)
10 (33.3)
6 (20.0)
3 (10.0)

P-value
<.0001
<.0001
<.0001
<.0001
<.0001
.1107
.2138
.0026

.6735

.5188

.0336
.4235
.3199
.3562

HPV = Human Papillomavirus; HNC = Head and Neck Cancer.

HPV and HPV vaccine knowledge by choice of specialty
(Table 2). A summary of the adjusted linear regression
results estimating HPV and HPV vaccine knowledge is pre
sented in Table 3. Compared with first-year students,
the second year (β = 2.62; 95% CI: 1.42, 3.82), third-year (β
= 6.19; 95% CI: 4.96, 7.41) and fourth-year (β = 6.75; 95% CI:
5.17, 8.33) students had higher HPV and HPV vaccine
knowledge. Males (β = −1.53; 95% CI: −2.53, −0.52) and
nonwhite (β = −1.05; 95% CI: −2.07, −0.03) medical students
had lower HPV and HPV vaccine knowledge in comparison
to their female and white counterparts. Marital status, num
ber of oral sexual partners, and number of vaginal sexual
partners had no significant association with HPV and HPV
vaccine knowledge.
HPV-associated HNC knowledge
The mean (SD) HPV-associated HNC knowledge was 7.2
(2.1) out of a maximum score of 12 (Table 1). There was

a statistically significant difference in HPV and HPV vac
cine knowledge (p < .001) (Figure 1b). First-year students
had the lowest mean score at 6.0 (1.9), while fourth-year
students had the highest at 8.7 (1.9) (Figure 1b). There
was no difference in HPV-associated HNC knowledge by
choice of specialty (Table 2). A summary of the adjusted
linear regression results estimating HPV-associated HNC
knowledge is presented in Table 3. In the multivariable
analyses, second-year (β = 1.37; 95% CI: 0.78, 1.96), thirdyear (β = 1.84; 95% CI: 1.24, 2.45), and fourth-year (β =
2.50; 95% CI: 1.72, 3.29) students had higher HPVassociated HNC knowledge compared with first-year stu
dents. Nonwhite medical students had lower HPVassociated HNC knowledge (β = −0.86; 95% CI: −1.37,
−0.36) compared with whites. There was no difference
observed in HPV-associated HNC knowledge by sex, mar
ital status, number of lifetime oral sexual partners, and
number of lifetime vaginal sexual partners.
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a
25.0

23.3
22.2
19.1

20.0

16.2
15.0

10.0

5.0

0.0

Year 1

Year 2

Year 3

Year 4

b
10.0
8.7

9.0
8.0
8.0

7.4

7.0
6.1
6.0

5.0
4.0
3.0
2.0
1.0
0.0
Year 1

Year 2

Year 3

Year 4

Figure 1. The average (a) HPV and HPV vaccine knowledge (b) HPV-associated HNC knowledge by year of study (n = 247).

Table 2. HPV and the vaccine knowledge, HPV-associated HNC cancer knowledge, and specific knowledge questions assessing HPV’s association with HNC or cervical
cancer by specialty.
Mean ± SD or n (%)
Specialty

HPV and the Vaccine Knowledge
HPV-associated HNC Knowledge
HPV causes HNC
Yes
No
HPV causes Cervical Cancer
Yes
No

Total
n=247
19.4 ± 4.6
7.2 ± 2.1

Pediatrics
48 (19.4)
20.2 (3.4)
7.1 (2.0)

Family Medicine
26 (10.5)
20.0 (5.2)
7.5 (2.3)

Internal Medicine
64 (25.9)
19.2 (4.8)
7.0 (2.2)

Surgery
41 (16.6)
18.3 (5.8)
7.3 (2.2)

Other specialties
68 (27.5)
19.4 (4.3)
7.3 (1.8)

53 (21.5)
194 (78.5)

5 (10.4)
43 (89.6)

5 (19.2)
21 (80.8)

12 (18.8)
52 (81.2)

10 (24.4)
31 (75.6)

21 (30.9)
47 (69.1)

179 (72.5)
68 (27.5)

35 (72.9)
13 (27.1)

21 (80.8)
5 (19.2)

45 (70.3)
19 (29.7)

31 (75.6)
10 (24.4)

47 (69.1)
21 (30.9)

P-value
.3633
.8386
.1065
.8021

HPV = Human Papillomavirus; HNC = Head and Neck Cancer.

HPV association specific knowledge questions
Similar to the two aggregate knowledge scores, specific ques
tions assessing knowledge of HPV’s association with HNC
and HPV’s association with cervical cancer exhibited
increased rate of correct responses with increasing year of
study (p < .001) (Table 1). There were no significant differ
ences in either knowledge by specialty choice (Table 2).
Table 4 summarizes logistic regression results of individual

knowledge questions regarding HPV’s association with HNC
or cervical cancer. No statistically significant differences were
observed by any covariate analyzed, with the exception that
first-year students show a decreased odds as compared to
fourth year students of identifying either HPV’s association
with HNC or HPV’s association with cervical cancer (aOR =
0.11; 95% CI: 0.03, 0.36; aOR = 0.29; 95% CI: 0.10, 0.83,
respectively).
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Table 3. Linear regression estimating relative risks of HPV and the vaccine, and
HPV-associated HNC cancer knowledge.

Table 4. Logistic regression estimating odds ratio of individual knowledge ques
tions regarding HPV’s association with HNC or cervical cancer.
Adjusted OR (95% CI)

Adjusted β (95% CI)

Year of study
First Year
Second Year
Third Year
Fourth Year
Sex
Female
Male
Race
White
Nonwhite
Marital status
Married
Single but Dating
Single and not Dating
Number of oral sexual partners
None
One
≥Two
Number of vaginal sexual
partners
None
One
≥Two
Specialty
Pediatrics
Family Medicine
Internal Medicine
Surgery
Other specialties

HPV & the Vaccine

HPV-associated
HNC

Ref
2.62 (1.42, 3.82)
6.19 (4.96, 7.41)
6.75 (5.17, 8.33)

Ref
1.37 (0.78, 1.96)
1.84 (1.24, 2.45)
2.50 (1.72, 3.29)

Ref
-1.53 (−2.53,
−0.52)

Ref
0.18 (−0.32, 0.68)

Ref
-1.05 (−2.07,
−0.03)

Ref
-0.86 (−1.37,
−0.36)

Ref
0.28 (−1.05, 1.61)
−0.45 (−1.64, 0.74)

Ref
0.16 (−0.50, 0.82)
0.17 (−0.43, 0.76)

Ref
0.51 (−1.11, 2.14)
0.44 (−1.21, 2.08)

Ref
0.61 (−0.20, 1.42)
−0.04 (−0.85, 0.78)

Ref
0.46 (−1.00, 1.93)
<0.01 (−1.63, 1.63)

Ref
0.02 (−0.70, 0.75)
0.15 (−0.66, 0.96)

Ref
−0.50 (−2.27, 1.28)
−0.46 (−1.91, 1.00)
−1.00 (−2.64, 0.63)
0.30 (−1.18, 1.79)

Ref
0.30 (−0.58, 1.18)
<0.01 (−0.72, 0.72)
0.37 (−0.44, 1.18)
0.30 (−0.44, 1.04)

CI = Confidence Interval; HPV = Human Papillomavirus; HNC = Head and Neck
Cancer.

Discussion
This study aimed to identify differences in knowledge of HPV,
HPV vaccine, and head HNC among medical students. Our
results indicate that there are gaps in knowledge of both HPV
vaccine and HPV-associated HNC among medical students.
While we observed a pattern of increased knowledge levels
with increasing training from first year to fourth, we also
observed differences in HPV vaccine knowledge based on sex
and race and differences in knowledge of HPV’s association
with HNC based on race. Our results provide some evidence
that, as primary stakeholders in HPV vaccine communication,
education, and uptake,18 this next generation of clinical provi
ders may need more education about the HPV vaccine
themselves.
The current literature regarding prevention and outcomes
of HPV-associated cancer is rapidly evolving. In the current
study, the mean score for HPV and HPV vaccine knowledge
was 19.4 out of 24, and knowledge HPV-associated HNC was
7.2 out of 12. In a previous study of university students, 81%
had less than average knowledge scores. However, participants
were university without a medical background.34 In another
survey of medical students in Alabama, participants had simi
lar knowledge levels as the current study, but the study focused
mainly on knowledge of HPV and HPV vaccine, not HPV’s
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Year of study
First Year
Second Year
Third Year
Fourth Year
Sex
Female
Male
Race
White
Nonwhite
Marital status
Married
Single but Dating
Single and not Dating
Number of oral sexual partners
None
One
≥Two
Number of vaginal sexual
partners
None
One
≥Two
Specialty
Pediatrics
Family Medicine
Internal Medicine
Surgery
Other specialties

HPV causes
HNC

HPV causes Cervical
Cancer

0.11 (0.03,
0.36)
0.48 (0.16, 1.42)
0.93 (0.32, 2.71)
Ref

0.29 (0.10, 0.83)

Ref
0.94 (0.46, 1.95)

Ref
0.54 (0.28, 1.05)

Ref
0.57 (0.26, 1.23)

Ref
0.62 (0.32, 1.21)

Ref
1.77 (0.66, 4.75)
1.11 (0.45, 2.76)

Ref
1.23 (0.51, 2.94)
0.93 (0.43, 2.01)

Ref
2.07 (0.58, 7.44)
3.07 (0.85,
11.04)

Ref
0.76 (0.25, 2.31)
1.06 (0.35, 3.24)

Ref
0.39 (0.13, 1.18)
0.42 (0.13, 1.37)

Ref
0.94 (0.35, 2.56)
0.53 (0.18, 1.56)

0.46 (0.11, 1.97)
Ref
1.26 (0.34, 4.72)
1.89 (0.47, 7.57)
3.33 (0.92,
12.04)

0.66 (0.19, 2.36)
Ref
0.67 (0.20, 2.29)
1.36 (0.35, 5.24)
0.74 (0.22, 2.52)

0.96 (0.31, 3.01)
3.63 (0.95, 13.80)
Ref

CI = Confidence Interval; HPV = Human Papillomavirus; HNC = Head and Neck
Cancer.

association with HNC.26 We found in the current study that
medical student knowledge of both outcome measures
remained inadequate, even among senior (4th year) medical
students.
We observed a “dose–response” association between year of
study and both HPV and HPV vaccine knowledge and HPVassociated HNC knowledge. Second, third- and fourth-year
medical students had higher knowledge scores than first-year
students. Similar associations between HPV knowledge, HPV
vaccine knowledge, and medical school year of study have been
described in recent literature.26 Likewise, the differences in
HPV-associated HNC knowledge by year of study in this
report are supported by a recent study reporting that medical
students identify incorrect HPV oncological associations as
often as its correct association with HNC.29 Unlike the current
study, however, a recent survey of 10 medical schools in
New York reported similar knowledge levels between thirdand fourth-year medical students regarding HNC.35 Taken
together, our findings from the Midwest, the study from
Alabama,26 a report from New York,35 as well as a national
survey of medical trainees (medical students and residents),29
all suggest that there might be an opportunity to improve the
medical school curricula with regard to HPV, HPV vaccine,
and HPV’s association with HNC. It seems at present that
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medical students may be not be adequately prepared to address
an issue like HPV vaccine uptake, which is a national
imperative.36 Given the poor rate of HPV vaccine uptake and
increasing incidence of HPV-related cancers, we suggest that
providing adequate knowledge about HPV, HPV-related can
cers, and the HPV vaccine should be addressed in medical
school curricula across the United States.
This study revealed lower HPV and HPV vaccine knowl
edge in male medical students. These results were contrast with
the observations made in a previous study, which did not find
any difference in knowledge based on sex.26 Studies have con
sistently shown that despite a higher incidence of HNC in men,
they have both lower HPV vaccine uptake, and HPV vaccina
tion knowledge than women.37–42 Many men consider HPV to
be a female issue as public health vaccination campaigns have
largely highlighted the vaccine as a preventive measure for
cervical cancer. In addition to differences in sex, we also
found a gap in knowledge by race, and nonwhite medical
students had significantly lower knowledge of HPV, HPV
vaccine, and HPV’s association with HNC. While differences
in HPV-associated HNC knowledge by race have been shown
in the general population, this trend has not been investigated
in the medical student population.37–39–43,44 This is important
because minorities are less likely to receive HPV vaccine
recommendations from providers despite more often relying
on primary care provider as a primary source of health
information.45–47 It is important to recognize these differences
in knowledge by race and sex in developing interventions for
these groups, and in improving the medical curricula. It is
particularly important as a physician’s recommendation of
the HPV vaccine remains one of the most important predictors
of uptake,18 and patient-physician racial concordance is asso
ciated with improved patients’ communication and overall
satisfaction with care provided.48,49 Thus, it is important that
future healthcare providers that are from minority racial back
ground receive training that equips them to engage in conver
sations that would increase HPV vaccine uptake, especially
when they provide care for racially concordant patients. This
might help mitigate the racial inequality in HPV vaccine
uptake.45,46
Limitations and strengths
This study has several limitations. First, as the sample
includes medical students from a single Midwestern academic
institution, generalizability is limited regarding medical stu
dents across the United States. However, two national surveys
reported overall similar results, which supports the external
validity of our conclusions.19,29 Second, the cross-sectional
study design precludes causal conclusions. There is also
a limited sample size of fourth-year medical students due to
the inclusion criteria of a maximum age of 26 years. Recently,
with increased enrollment of non-traditional medical stu
dents, the average age of medical students has risen. The
increasing number of medical students over 26 years is not
included in our study; however, we believe their exclusion
should not affect our findings as a majority of medical stu
dents as our cutoff age of 26 years falls within the average of
matriculating into medical school in the United States within

the last two decades.50 Lastly, our physician recommendation
of HPV vaccine assessment may not be reliable as it is possible
that a subset of respondents to this question may have been
vaccinated as children.
Despite these limitations, our study is one of few to examine
HPV-associated HNC knowledge in the medical student popu
lation, in addition to knowledge of HPV and HPV vaccine. The
study included comparable numbers of both male and female
participants, which contrasts with most previous studies which
included only females.

Implications
HPV vaccination for all below the age of 26 years and for
those between 27 and 45 years with certain risk factors,
based on a patient-physician shared decision-making.
Thus, there is a need for provider knowledge and recom
mendation of the vaccine. Evidence is growing regarding
inadequate physician communication and recommendation
of the HPV vaccine.21–24 Knowledge of HPV’s link to
oropharyngeal cancer is particularly important as HPVassociated oropharyngeal cancer has surpassed cervical can
cer as the leading HPV-associated cancer in the United
States.51 35Unlike cervical cancer, HPV vaccine is the only
primary prevention for oropharyngeal cancer, and the Food
and Drug Administration only recently extended the indi
cations for HPV vaccination to include preventing orophar
yngeal cancer.6 However, more individuals may be aware of
the link between HPV and cervical cancer than the link
between HPV and HNC.38 There are several reasons driv
ing this lack of knowledge of HPV’s link to HNC relative to
cervical cancer. For example, the natural history of cervical
cancer is more understood than oropharyngeal cancer.
Also, the HPV vaccine was first approved and heavily
marketed toward females for preventing cervical cancer,
and it was not until 2011 that the vaccine was approved
for use among males. Thus, it might be that even among
medical students, there may still be some lingering percep
tion of HPV being primarily an issue for women.
Thus, there is a need for improved knowledge regarding
HPV-related associations and interventions in healthcare pro
viders today. Our study showed that there are inadequate HPV
knowledge levels among medical students. Improving gaps in
HPV vaccine coverage, reducing HPV infection rates, and
advancing primary prevention of HPV-associated oropharyn
geal cancer all rely on new and robust educational interven
tions that begin with medical students, especially in males and
racial/ethnic minorities.

Conclusion
Our study shows that medical students have low knowledge of
HPV, the HPV vaccine, and the association between HPV and
HNC. There are pronounced disparities in knowledge by med
ical school year, sex, and race. Educational interventions must
address medical student knowledge to improve HPV vaccine
coverage and address the increasing incidence of HPVassociated oropharyngeal cancer.
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